Soft tissue sarcoma is a rare heterogeneous tumor with complex pathological types and obvious tumor heterogeneity. The current clinical treatment of soft tissue sarcoma mainly uses cytotoxic anti-tumor drugs, which have significant adverse reactions and poor tolerance. Alternative efficacious treatment with fewer side effects is urgently needed.
Sarcomas have witnessed high growth in the past few years. The rise in mortality due to cancer is rising the concern. Sarcomas grow in connective tissue; cells that connect or support other kinds of tissue in patients body. According to American Cancer Society, Inc., in 2021 about 13,460 new soft tissue sarcomas will be diagnosed (7,720 in males and 5,740 in females) and about 5,350 people (2,840 males and 2,510 females) are expected to die of soft tissue sarcomas. The noticeable rise in number of patients suffering from cancer has raised the alarm for the development of new cancer drugs. Drugs manufacturer are investing high for the drugs development, heavy flow in clinical trials activities and collaborative approach between public and private players for R&D activities are factors expected to drive the growth of the global sarcoma market.
In 2016, The FDA granted Eli Lilly the accelerated approval for olaratumab for the treatment of adults with certain types of soft-tissue sarcoma. Olaratumab, a platelet-derived growth factor (PDGF) receptor-alpha–blocking monoclonal antibody is indicated, in combination with doxorubicin, for the treatment of adults with soft-tissue sarcoma.
In 2020, Junshi Biosciences, a global biopharmaceutical company, received approval from US Food and Drug Administration (FDA) for Orphan Drug designation to toripalimab for the treatment of soft tissue sarcoma. This approval is expected to help company to market new product and attract new customers with increase in revenue.
Government of developing countries is focused on strengthening the regional manufacturing capabilities. Favorable business and emergence of small and mid-size enterprises with innovative solutions are factors expected to augment the growth of sarcoma market. Factors such as side-effects of the medicines and complex product approval process by the government are expected to hamper the growth of global sarcoma market. In addition, lack of developed infrastructure for R&D activities is expected to challenge the growth of target market. However, rise in investment for drug development and from major players and increasing government spending on development of healthcare infrastructure are factors expected to create new opportunities for players operating in the sarcoma market over the forecast period. In addition, increasing awareness activities by the government and partnership activities are factors expected to support the revenue transaction of the target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global sarcoma market due to high patient pool suffering from cancer. In 2019, there were 12,750 cases of soft tissue sarcoma and 800-900 new cases of bone sarcomas will be diagnosed in the U.S. Government focus on R&D activities and introduction of new drugs from manufacturer are factors expected to support the growth of sarcoma market. In addition, increasing acquisition activities in order to enhance the business and increase the customer base is expected to boost the growth of sarcoma regional market.
The global sarcoma market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Sarcoma Market Segment Analysis, 2019
The global sarcoma market is segmented into drug therapy, type, distribution channel, and end use. The drug type segment is divided into chemotherapy, targeted therapy, immunotherapy, others. Among drug type the targeted therapy segment is expected to witness faster growth in the sarcoma market. The type segment is divided into branded and generic. Among end use the hospital segment is expected to account for major revenue share in the global sarcoma market. The players profiled in the report are Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG., Amgen Inc., AstraZeneca, Daiichi Sankyo Company, Limited., AB Sciences, AgonOX, Inc., Eisai Co., Ltd., GlaxoSmithKline, plc., and Pfizer, Inc.
Market By Drug Therapy
Market By Drug Type
Market By Distribution Channel
Market By End-Users
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Drugs manufacturer are investing high for the drugs development, heavy flow in clinical trials activities and collaborative approach between public and private players for R&D activities are factors expected to drive the growth of global sarcoma market.
In drug therapy the targeted therapy segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., and Genentech Inc.
The North America is expected to account for major revenue share in the global market.
Factors such as side-effects of the medicines and complex product approval process by the government are expected to hamper the growth of global sarcoma market.